Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients
To verify the serological response mounted against antigenic peptides from HERV-Wenv protein, we analyzed 80 multiple sclerosis (MS) serum samples, 27 of which were re-analyzed after a 6-month follow-up IFN-β therapy, and 73 healthy controls. Indirect ELISAs were carried out to detect antibodies spe...
Saved in:
Published in | Journal of neuroimmunology Vol. 280; pp. 66 - 68 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
15.03.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0165-5728 1872-8421 |
DOI | 10.1016/j.jneuroim.2015.03.003 |
Cover
Summary: | To verify the serological response mounted against antigenic peptides from HERV-Wenv protein, we analyzed 80 multiple sclerosis (MS) serum samples, 27 of which were re-analyzed after a 6-month follow-up IFN-β therapy, and 73 healthy controls. Indirect ELISAs were carried out to detect antibodies specific for all the synthetic peptides derived from HERV-Wenv. Two antigenic peptides, HERV-Wenv93–108 (31.25%, p<0.0001) and HERV-Wenv248–262 (15%, p=0.02), were highly recognized by MS patients' antibodies when compared to healthy subjects. Moreover, antibody titer against these two peptides slightly decreased after six months of IFN-β-based therapy.
•Six antigenic peptides from HERV-Wenv protein were identified.•A peptide-based indirect ELISA was used to screen a population of 80 MS and 73 HCs.•Only two peptides were capable of inducing a strong humoral response in MS subjects.•Antibody values against these two peptides decreased after six months of IFN-β therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0165-5728 1872-8421 |
DOI: | 10.1016/j.jneuroim.2015.03.003 |